• Adamtsl3, MMP9, and Adult Cortical Plasticity

  2026-10-07

  The 2026 Molecular Psychiatry study identifies Adamtsl3 as a cell-autonomous regulator of perineuronal-net integrity in parvalbumin-positive interneurons and links its loss to increased MMP9 activity, oxidative stress, and renewed adult cortical plasticity. Its convergent genetic, morphological, biochemical, and pharmacological evidence provides a mechanistic framework for studying extracellular-matrix regulation in schizophrenia-related biology, while remaining limited by its mouse-cortex focus.

• Iron Stress Reprograms Enterocyte Metabolism

  2026-10-06

  Navazesh and Ji show that iron deficiency and iron excess produce distinct metabolic and transcriptional responses in IPEC-J2 enterocytes. The study’s paired perturbation design links iron status with proliferation, inflammatory signaling, glycolysis, the TCA cycle, cholesterol biosynthesis, and partial metabolic recovery after repletion.

• Z-VDVAD-FMK: Evidence, Scope, and Limitations

  2026-10-06

  A source-grounded overview of Z-VDVAD-FMK, distinguishing vendor-described caspase inhibition from evidence in a 2025 study of HOXC8, caspase-1, and pyroptosis in non-small cell lung cancer.

• GPR35–KLF5 Circuitry in Epithelial Repair

  2026-10-05

  A 2026 Cell Death and Disease study identifies a tryptophan-metabolite sensing mechanism in which GPR35 connects mucosal damage signals to KLF5-dependent epithelial repair. The findings position the GPR35–KLF5 axis as a mechanistic framework for ulcerative colitis research while remaining preclinical and model-dependent.

• JHU-083: Evidence, Context, and Research Limits

  2026-10-05

  JHU-083 is described by APExBIO as a 6-diazo-5-oxo-L-norleucine precursor and selective glutaminase antagonist for research involving cerebral CD11b cells and experimental cerebral malaria. This overview separates that supplier-level description from peer-reviewed evidence supplied for a distinct α-amanitin liver-injury study. It explains the proposed relevance to glutaminase pathway research, glutamate biology, and neurological disease models while emphasizing the absence of independent JHU-083 efficacy data, human evidence, and direct support for therapeutic or cross-organ conclusions.

• Haloprogin: Evidence from a 1970 Topical Study

  2026-10-04

  Harrison and colleagues showed that Haloprogin combined dermatophyte activity comparable to tolnaftate with additional activity against Candida species and selected Gram-positive bacteria. The study’s value lies in connecting comparative in vitro testing with a topical guinea pig model, while its age, limited organism coverage, and lack of molecular-mechanism data constrain modern interpretation.

• Sunitinib: Five Questions About the Evidence

  2026-10-03

  A source-grounded overview of Sunitinib, RTK inhibition, ATRX-deficient glioma findings, evidence quality, interpretation, applicability, and key limitations.

• Sisomicin Activity Against Clinical Isolates

  2026-10-02

  This historical study compared sisomicin with gentamicin, tobramycin, amikacin, butirosin, and kanamycin across 565 clinical isolates. Its main contribution was a structured, head-to-head MIC assessment showing broad activity against Gram-negative bacilli, while also revealing cross-resistance between sisomicin and gentamicin or tobramycin.

• ASB5 in Muscle Satellite Cells: Marker, Not Driver

  2026-10-01

  The reference study identifies ASB5 as a highly specific marker of muscle satellite cells and myogenic progenitors while showing that Asb5 is dispensable for normal skeletal muscle development, growth, regeneration, and satellite-cell behavior. Its combination of single-cell transcriptomics, CRISPR-Cas9 knockout, myofiber assays, injury analysis, and qPCR provides a useful framework for separating cell-state markers from essential regulators.

• THZ1: Covalent CDK7 Inhibition

  2026-10-01

  THZ1 is a covalent CDK7 inhibitor that irreversibly modifies CDK7 C312 and suppresses RNA polymerase II C-terminal-domain phosphorylation. Its reported biochemical and T-cell acute lymphoblastic leukemia (T-ALL) activity supports focused transcriptional and cancer biology research, but the compound remains a research-use reagent rather than a clinical treatment.

• Computational Hapten Design for Amatoxin Biosensing

  2026-09-30

  The 2026 reference study combines molecular similarity analysis, quantum chemistry, and monoclonal antibody engineering to improve simultaneous recognition of amatoxins and phallotoxins. Its dual-target fluorescent immunochromatographic assay achieved low microgram-per-kilogram detection limits in mushroom matrices, supporting rapid screening where laboratory mass spectrometry is impractical.

• Bafilomycin C1 in High-Content Cell Assays

  2026-09-30

  Bafilomycin C1 converts lysosomal acidification into a controllable phenotypic perturbation for autophagy assays, iPSC-cardiomyocyte imaging, and mechanistic toxicity studies. This workflow explains how to dose, image, analyze, and troubleshoot the compound without mistaking organelle stress for primary cardiotoxicity.

• Machine-Learning Discovery of Senolytic Compounds

  2026-09-29

  The reference study shows that machine-learning models trained only on published screening data can prioritize senolytic candidates despite limited and heterogeneous datasets. Computational screening followed by human-cell validation identified ginkgetin, periplocin, and oleandrin, establishing a lower-cost route for early senolytic discovery while highlighting important limits in assay transferability and selectivity.

• AZ 10417808 in ATRX-Deficient Glioma

  2026-09-29

  Explore how AZ 10417808 can be evaluated in ATRX-deficient glioma research through genotype-aware assay design, RTK/PDGFR biology, and combination testing with temozolomide. This evidence-focused guide emphasizes what the literature supports and which conclusions require direct validation.

• Nigericin: Translating Ion Gradients into Strategy

  2026-09-28

  Nigericin is more than a membrane-active antibiotic: it is a controllable potassium/hydrogen ion carrier that turns intracellular pH and mitochondrial ion transport into experimental variables. This thought-leadership guide connects its mechanism with anticancer assay design, GSDMD-linked cellular pyrokinesis, and a carefully bounded hypothesis for metabolism-informed antimicrobial research.

8181 records 1/546 page Next 12345 下5页 Last page